High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments.
IL-33
PD-L1
immunohistochemistry
interleukin 33
oral squamous cell carcinoma
prognosis
programmed cell death-ligand 1
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
01 Sep 2021
01 Sep 2021
Historique:
received:
12
07
2021
revised:
26
08
2021
accepted:
27
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
The markers of the tumor microenvironment (TME) are promising prognostic and predictive factors in oral squamous cell carcinoma (OSCC). The current study aims to analyze the immunohistochemical expression of programmed cell death-ligand 1 (PD-L1) and interleukin-33 (IL-33) in a cohort of 95 chemonaïve OSCCs. PD-L1 and IL-33 were assessed separately in tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs). High PD-L1 expression in TILs was associated with better overall survival (OS) in univariate analysis. Tumors localized in the floor of the oral cavity and tongue tended to have a lower percentage of PD-L1-positive TCs when compared to other locations. PD-L1 expression on TCs had no prognostic significance when the whole cohort was analyzed. However, along with the T descriptor (TNM 8
Identifiants
pubmed: 34572318
pii: biomedicines9091132
doi: 10.3390/biomedicines9091132
pmc: PMC8471659
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Infect Immun. 2020 Apr 20;88(5):
pubmed: 32041789
J Craniomaxillofac Surg. 2019 Jan;47(1):33-40
pubmed: 30466788
Oral Oncol. 2011 Dec;47(12):1148-53
pubmed: 21911310
Cancers (Basel). 2021 Apr 07;13(8):
pubmed: 33916925
Semin Immunol. 2013 Dec 15;25(6):449-57
pubmed: 24230466
Cancer Med. 2020 Jul;9(13):4791-4807
pubmed: 32383556
Arch Med Sci. 2020 Nov 13;17(1):207-217
pubmed: 33488873
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
J Oral Maxillofac Surg. 2017 May;75(5):969-977
pubmed: 27916470
Oncoimmunology. 2012 Nov 1;1(8):1223-1225
pubmed: 23243584
Cancer Immunol Immunother. 2020 Mar;69(3):465-476
pubmed: 31950224
Cancers (Basel). 2021 Jun 30;13(13):
pubmed: 34209038
Mod Pathol. 2018 Jun;31(6):910-922
pubmed: 29416107
Biomedicines. 2021 Jan 20;9(2):
pubmed: 33498270
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819867354
pubmed: 31370775
J Pathol. 2013 Oct;231(2):180-9
pubmed: 23775566
Acta Med Okayama. 2017 Jun;71(3):219-226
pubmed: 28655941
Sci Rep. 2016 Nov 14;6:36956
pubmed: 27841362
Oncotarget. 2017 Aug 3;8(39):66178-66194
pubmed: 29029502
Oral Dis. 2020 Oct;26(7):1414-1423
pubmed: 32406589
Int J Oncol. 2017 Jan;50(1):41-48
pubmed: 27922697
Front Immunol. 2019 Mar 20;10:522
pubmed: 30949175
Oral Oncol. 2015 Jan;51(1):90-5
pubmed: 25283344
Pathology. 2016 Oct;48(6):574-80
pubmed: 27590194
Oncotarget. 2016 Sep 20;7(38):61069-61080
pubmed: 27517629
Int J Mol Sci. 2021 May 28;22(11):
pubmed: 34071419
Cancers (Basel). 2019 Mar 28;11(4):
pubmed: 30925774
Pathol Oncol Res. 2018 Jul;24(3):497-505
pubmed: 28669079
Ann Oncol. 2017 Aug 1;28(8):1923-1933
pubmed: 28838214
Int J Oral Maxillofac Surg. 2018 Jul;47(7):836-845
pubmed: 29395669
J Clin Oncol. 2017 Nov 1;35(31):3601-3609
pubmed: 28880746
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Auris Nasus Larynx. 2014 Dec;41(6):552-7
pubmed: 25193287
Cancer Treat Rev. 2020 Mar;84:101977
pubmed: 32018128
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Anticancer Res. 2019 Jun;39(6):3039-3046
pubmed: 31177146
Ann Oncol. 2017 Aug 1;28(8):1934-1941
pubmed: 28460011
Int J Oncol. 2020 Apr;56(4):909-920
pubmed: 32319563
APMIS. 2018 Sep;126(9):732-738
pubmed: 30160018
Cancer Immunol Immunother. 2013 May;62(5):863-73
pubmed: 23359088
Oral Oncol. 2015 Nov;51(11):1004-1010
pubmed: 26365985
Clin Cancer Res. 2016 Feb 1;22(3):704-13
pubmed: 26408403
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724788
Sci Rep. 2017 May 11;7(1):1755
pubmed: 28496107
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Dec;128(6):631-638
pubmed: 31495715
Oncotarget. 2015 Aug 28;6(25):20902-20
pubmed: 26041877
Int J Oral Maxillofac Surg. 2018 May;47(5):568-577
pubmed: 28969885
Biomolecules. 2019 May 25;9(5):
pubmed: 31130612
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):546-554
pubmed: 30487133
Biomedicines. 2021 Jun 08;9(6):
pubmed: 34201050
Sci Rep. 2017 Sep 18;7(1):11773
pubmed: 28924229
Cancer Immunol Immunother. 2011 Jul;60(7):965-74
pubmed: 21442435
For Immunopathol Dis Therap. 2015;6(1-2):7-17
pubmed: 28286692
Immunotherapy. 2016 Jun;8(6):733-46
pubmed: 27197541
BMC Cancer. 2020 Mar 17;20(1):229
pubmed: 32183719
Cancer Res. 2017 Nov 15;77(22):6365-6374
pubmed: 28947422
Anticancer Res. 2017 Mar;37(3):1417-1424
pubmed: 28314313
Biomedicines. 2021 Jun 02;9(6):
pubmed: 34199461
J Surg Oncol. 2021 Jan;123(1):141-148
pubmed: 32974936
PLoS One. 2015 Nov 12;10(11):e0142656
pubmed: 26562534
Oncotarget. 2016 Mar 15;7(11):12024-34
pubmed: 26918453
Adv Exp Med Biol. 2016;941:21-29
pubmed: 27734407
Mucosal Immunol. 2017 May;10(3):650-660
pubmed: 27731324
Maxillofac Plast Reconstr Surg. 2019 Dec 5;41(1):56
pubmed: 31857991
Carcinogenesis. 2018 Mar 8;39(3):397-406
pubmed: 29346528
Int J Mol Sci. 2015 Oct 12;16(10):24094-110
pubmed: 26473842
J Cell Biochem. 2020 Feb;121(2):1855-1869
pubmed: 31633227